Feasibility Study of Adjuvant Chemotherapy Using Taxane Plus Carboplatin for High-Risk Patients With Uterine Cervical Non-Squamous Cell Carcinoma After Radical Hysterectomy

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
Seiya SatoJunzo Kigawa

Abstract

We conducted this study to evaluate the efficacy and safety of adjuvant chemotherapy using taxane plus carboplatin (CBDCA) for high-risk stage IB-IIB patients with uterine cervical non-squamous cell carcinoma after radical hysterectomy. Thirty-seven patients were eligible. Pelvic lymph node involvement and/or parametrial invasion were defined as high-risk factors. The patients were treated with 6 cycles of paclitaxel (PTX, 175 mg/m(2)) or docetaxel (DTX, 60 mg/m(2)) followed by CBDCA (area under the curve, 6) every 3 weeks. The primary end point was 2-year progression-free survival (PFS) rate, and the secondary end point was the assessment of adverse events. Twenty-two patients received PTX/CBDCA (TC) chemotherapy, and the remaining 15 patients underwent DTX/CBDCA (DC) chemotherapy. The 2-year PFS rate was 62.1% (95% confidence interval, 44.6%-75.5%). Patients receiving DC chemotherapy showed a better 2-year PFS rate compared to those with TC chemotherapy, but the difference was not statistically significant (80.0% vs 50.0%, P = 0.1400). The most common grade 3/4 adverse events were hematologic toxicities, which were generally well tolerable. Nonhematologic toxicity was generally mild. Taxane and CBDCA combination chemotherapy,...Continue Reading

References

Apr 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W A PetersD S Alberts
Oct 4, 2000·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·T IrieN Terakawa
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P CurtinR D Alvarez
Nov 23, 2005·Gynecologic Oncology·Muneaki ShimadaNaoki Terakawa
Feb 22, 2008·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Oct 22, 2008·The Journal of Obstetrics and Gynaecology Research·Masayoshi HosakaNoriaki Sakuragi
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bradley J MonkDavid Cella
Jan 24, 2012·Gynecologic Oncology·Vijaya GalicJason D Wright
Aug 1, 2014·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Mikio MikamiUNKNOWN Disease Committee of Uterine Cervical and Vulvar Cancer, Japanese Gynecologic Oncology Group
Mar 4, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ryo KitagawaHiroyuki Yoshikawa
Mar 25, 2015·International Journal of Clinical Oncology·Yasuhiko EbinaHiroyuki Yoshikawa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Adenocarcinoma, Clear Cell

Clear Cell Adenocarcinoma is a tumor that arises in the female genital tract and is characterized by cells that appear clear under the microscope. Discover the latest research here.